XCancer

Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1

Description:

The study should evaluate the biological distribution of \[123I\]I-DARPIN-Ec1 in patients with lung and ovarian cancer The primary objective are: 1. To assess the distribution of \[123I\]I-DARPIN-Ec1 in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of \[123I\]I-DARPIN-Ec1. 3. To study the safety and tolerability of the drug \[123I\]I-DARPIN-Ec1 after a single injection in a diagnostic dosage. The secondary objective are: 1\. To compare the obtained \[123I\]I-DARPIN-Ec1 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in lung and ovarian cancer patients.

Sponsor:

Tomsk National Research Medical Center of the Russian Academy of Sciences

Phase:

Phase 1

Contacts:

Vladimir I Chernov, MD, Prof (STUDY_DIRECTOR)

Government Study Link:

NCT06386653 - Click here to see study on

ClinicalTrials.gov

DARPIN-Ec1

Isotope(s):
Target(s):
  • EpCAM
Ligand Class: Small Proteins and Antibody Fragments
Inclusion
  • Clinical and radiological diagnosis of lung and ovarian cancer with histological verification.
Exclusion
  • Clinical and radiological diagnosis of lung and ovarian cancer with histological verification.